drugset / Trial / NCT07559240

A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants

NCT07559240

Phase 1 Not yet recruiting 30 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic profile and safety of a single subcutaneous injection of HDM1005 solution in participants with impaired kidney function compared to healthy participants.

Timeline

Start
2026-05-15
Primary completion
2026-06-12
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM1005 Unknown 2 mg Subcutaneous

Indications